Purple Biotech (PPBT)

• Market cap: $5.39M
• 1 day: 0.77%
• 5 days: 3.79%
• 1 month: -13.99%
• 3 months: -18.76%
• 6 months: -72%
• Year to date: -8.84%
• 1 year: -81.65%
• 5 years: -99.57%
• 10 years: -99.88%
• Sector: Healthcare
• Industry: Biotechnology

About: Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

Employees: 7